Huntsman Q1 2026 slides: cost cuts deliver as leverage climbs to 6.1x

Huntsman reported Q1 revenue of $1.42B, adjusted EBITDA of $73M, and a widened net loss of $53M, while net debt leverage rose to 6.1x and all three major ratings agencies downgraded the company to junk territory. Offsetting some weakness, cost realignment beat targets at a $110M annualized run rate versus a $100M goal, and management guided Q2 adjusted EBITDA to $100M-$130M, above Q1 levels. The dividend was cut to $0.0875 from $0.25 as the company works to preserve cash amid supply chain disruptions and elevated raw material costs.

Analysis

The market is treating this like a simple turnaround story, but the more important signal is capital structure fragility. When a cyclical chemical name loses investment-grade access while still generating only modest EBITDA, equity becomes a residual claim on pricing discipline and working-capital timing; that makes the stock highly sensitive to any delay in the expected second-half margin recovery. The lower dividend is not just a cash-preservation move — it is a tacit admission that the business now has to de-lever before it can resume any meaningful capital return narrative.

The biggest second-order winner is likely not HUN’s direct competitors, but customers and suppliers with cleaner balance sheets and less Middle East exposure. If Huntsman must prioritize pricing over volume to defend EBITDA, downstream formulators will have an incentive to dual-source away from exposed supply chains, which can take share from the weakest regional producers and reward faster-logistics alternatives in Europe and the Americas. In that sense, the current disruption can actually accelerate customer defection in Performance Products, where lost volume may prove stickier than management implies.

The contrarian setup is that the earnings bridge is less about cyclical demand than about cost reset completion. If the announced savings flow through while working capital normalizes, FCF can improve faster than EBITDA, and that matters because distressed-credit equity rallies are often driven by liquidity milestones, not operating headlines. The risk is that the market is overestimating how quickly price actions offset raw material inflation; if crude-linked inputs stay volatile for another quarter, the 2Q guide could become the high-water mark rather than the start of a recovery.

For now, this looks like a tradable squeeze rather than a durable rerating: the equity can grind higher on any confirmation of sequential EBITDA improvement, but the bond stack should remain cautious until leverage moves decisively below 5x. The key watchpoint over the next 30-90 days is whether Advanced Materials can keep growing enough to mask weakness elsewhere; if not, the credit story reasserts itself and the stock likely revisits distress-style multiples.

Key Decisions for Investors

• Short HUN common into strength over the next 2-6 weeks; use the post-earnings bounce as liquidity to express the view that leverage and rating pressure cap upside. Risk/reward favors a retest lower if 2Q pricing benefits slip by even 10-15% versus guide.
• Pair trade: long AXTA / short HUN for 1-3 months. The thesis is cleaner end-market exposure and less balance-sheet risk on the long side versus a levered, supply-chain-encumbered cyclical on the short side.
• Buy HUN 3-6 month put spreads only on rallies above recent post-earnings levels; structure for a limited-premium bearish expression tied to any disappointment in sequential EBITDA or free cash flow conversion.
• Watch HUN bonds and CDS as the higher-conviction signal than the stock. If unsecured spreads fail to tighten meaningfully after earnings, reduce any equity long exposure immediately; the credit market is likely to lead the next move.
• For event-driven investors, consider a tactical long only if management confirms 2Q EBITDA lands at the high end of guidance and working capital releases continue. In that case, a 1-2 month squeeze trade could work, but stop tightly if geopolitical disruptions worsen.